# Metastatic Pancreatic Ductal Adenocarcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma

> No upcoming FDA catalysts in metastatic Pancreatic Ductal Adenocarcinoma; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for metastatic Pancreatic Ductal Adenocarcinoma?

No upcoming FDA catalysts in metastatic Pancreatic Ductal Adenocarcinoma; 3 past events are recorded. ClinicalTrials.gov: "NCT05630183 (A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Agenus Inc.." [Calendar and source filings](https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05630183 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 18, 2025 | [Tecentriq® (atezolizumab) primary completion](https://sec-api.dev/pdufa/atezolizumab) | NVCR | Metastatic Pancreatic Ductal Adenocarcinoma | completed | "NCT06390059 (EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-18 (ACTUAL); Lead Sponsor NovoCure Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06390059)) |
| January 5, 2026 | [SULANDA® (surufatinib) trial start](https://sec-api.dev/pdufa/surufatinib) | HCM | metastatic pancreatic ductal adenocarcinoma | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, January 5, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000002/hcm-20260105xex99d1.htm)) |
| January 5, 2026 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Pancreatic Ductal Adenocarcinoma | completed | "NCT05630183 (A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630183)) |

## Drugs

- [Tecentriq® (atezolizumab)](https://sec-api.dev/pdufa/atezolizumab) (NVCR)
- [SULANDA® (surufatinib)](https://sec-api.dev/pdufa/surufatinib) (HCM)
- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab) (AGEN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Pancreatic Ductal Adenocarcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma

```bibtex
@misc{secapidev_indications_metastatic_pancreatic_ductal_adenocarcinoma_20261116,
  title        = {Metastatic Pancreatic Ductal Adenocarcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_pancreatic_ductal_adenocarcinoma_20261116","title":"Metastatic Pancreatic Ductal Adenocarcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
